Wednesday, April 21, 2021

Investor Ideas #Potcasts 555, #Cannabis News and #Stocks on the Move; (CSE: $XTRX.C) (TSX: $FAF.TO) (CSE: $AION.C) (CSE: $IPOT.C) (OTC: $ISCNF) (TSX: $WEED.TO) (NASDAQ: $CGC)



Investor Ideas #Potcasts 555, #Cannabis News and #Stocks on the Move; (CSE: $XTRX.C) (TSX: $FAF.TO) (CSE: $AION.C) (CSE: $IPOT.C) (OTC: $ISCNF) (TSX: $WEED.TO) (NASDAQ: $CGC)


Delta, Kelowna, BC, April 21, 2021 ( Newswire), a global news source covering leading sectors including marijuana and hemp stocks and its potcast site,  release today’s podcast edition of  cannabis news and stocks to watch plus insight from thought leaders and experts.


Listen to the podcast:


Read this in full at


Hear Investor ideas cannabis potcast on iTunes  


Hear the investor ideas potcast on Spotify


Today’s podcast overview/transcript:


Good afternoon and welcome to another episode of "Potcast" featuring cannabis news, stocks to watch as well as insights from thought leaders and experts.


Today’s podcast is sponsored by Phyto Extractions Inc. (CSE:XTRX), an agricultural-scale cannabis extraction, distillation and product manufacturer located in Langley, BC at its co-located Health Canada Licensed Standard Processing (extraction, no cultivation), Sales (extracts, topicals, and edibles) through Adastra Labs Inc. and Analytical Testing Laboratory through Chemia Analytics Inc. Adastra Labs also has a pending Health Canada R&D license amendment.


In today’s podcast we look at a few private and public company announcements.


Fire & Flower Holdings Corp. (TSX: FAF) (OTCQX: FFLWF) and its indirect wholly-owned subsidiary Hifyre Inc., today announced the milestone achievement of 250,000 Spark PerksTM members across the Fire & Flower retail network.


Spark Perks members receive special benefits where permitted, including: Spark Fastlane TM click-and-collect checkout, personalized recommendations, curbside pickup, free rapid delivery, and exclusive deals. No cannabis purchase is required to join the free program.

The Sparks Perks program is now available across all Fire & Flower banners including Friendly Stranger, Happy Dayz and Hotbox and delivers personalized product recommendations to members.


"A core metric in our business is lifetime customer value and the cost of customer acquisition. We believe Spark Perks customers have the highest lifetime customer value in the industry through their larger basket sizes, more frequent visits and the diversity of products they consume," said Trevor Fencott, Chief Executive Officer of Fire & Flower.


"While growing rapidly, we have also focused on a low cost of customer acquisition. Although metrics such as same store sales are important, as an evolved technology-enabled retail company we focus on customer engagement metrics that will be critical as our platform scales to the U.S."


Key Metrics from the Spark Perks Program:

       Members who order from Same Day Rapid Delivery spend 110 per cent more than non-members and have 90 per cent larger baskets than non-members

       Members served through Fastlane pickup spend 49 per cent more than non-members in-store

       Members transacting in-store have 27 per cent larger basket sizes than non-members with 19 per cent more items in their baskets


The Spark Perks program leverages the HifyreTM advanced digital retail and analytics platform. Hifyre is the leading Canadian data and analytics platform within the cannabis industry and recently entered into a strategic agreement with BDS Analytics Inc. ("BDSA") to incorporate Hifyre's Canadian digital retail and analytics into BDSA's existing online U.S.-based market research platform. As part of the agreement, BDSA will offer Hifyre IQ Canadian cannabis data to its U.S.-based clients and Hifyre will be able to provide U.S. data from BDSA to its Canadian clients, allowing both companies to offer enhanced, cross-border data to their respective consumer bases.


The company also announced that it will release its financial and operational results for fourth quarter and the fiscal year of 2020 ended January 30, 2021 before financial markets open on April 27, 2021. The results will be available on SEDAR and on the Company's website at


Following the release of the results, Fire & Flower will host a conference call with Trevor Fencott, President and Chief Executive Officer, and Nadia Vattovaz, Executive Vice President, Operations and Chief Financial Officer at 8:30 a.m. EDT on April 27, 2021. The conference call will discuss Fire & Flower's fourth quarter and fiscal year 2020 financial and operational results and updates on the Company's plans for fiscal year 2021.


Aion Therapeutic Inc. (CSE: AIONannounced today that its proprietary and patented combinatorial mushroom preparations AION F7 and AION F8 (collectively, the "Aion Mushroom Preparations" or "Preparations") showed high efficacy in killing HER2+ breast cancer cells, ER+/PR+ breast cancer cells, and triple-negative breast cancer cells by direct cytotoxicity.


As shown in recently completed third-party independent and carefully controlled 3D-spheroid cell culture studies performed at BIOENSIS laboratories, these cytotoxicity studies demonstrated direct killing of the breast cancer cells by the Aion Mushroom Preparations, which suggests such preparations may be effective in treating HER2+ breast cancer, ER+/PR+ breast cancer, and the very difficult to treat triple-negative breast cancer, with each of these types of breast cancers tested independently.


In separate independent studies at BIOENSIS laboratories using the Antibody-Dependent Cellular Cytotoxicity (ADCC) assay and the Antibody-Dependent Cellular Phagocytosis (ADCP) assay, the Aion Mushroom Preparations also demonstrated enhanced cell killing of HER2+ breast cancer cells via stimulation of the immune system. The Preparations showed similar effectiveness as trastuzumab, a monoclonal antibody treatment sold under the brand name Herceptin, manufactured by Roche and is a US FDA approved medication useful for treating HER2+ breast cancer that is either early-stage or advanced-stage/metastatic.


Herceptin (trastuzumab) is the leading breast cancer drug with annual global sales of around $7 billion.1 Other FDA approved biosimilar trastuzumab products include: Trazimera (Pfizer), Kanjinti (Amgen), Ontruzant (Merck), Herzuma (Teva), and Ogivri (Mylan). When Aion Mushroom Preparations were combined with Trastuzumab, there was a greater than 60% increase in the killing of HER2+ breast cancer cells when compared to Trastuzumab used alone.


Based on these results, Dr. Herbert A. Fritsche, Chief Science Officer of Aion Therapeutic and former Professor and Director of Clinical Chemistry at the University of Texas, MD Anderson Cancer Center, stated, "The extremely exciting results obtained from these independent 3D cell culture studies suggests that when appropriate Aion Mushroom Preparations are used together, they may offer a dual approach to the killing of HER2+ breast cancer cells through two separate and distinct pathways (direct cytotoxicity and antibody dependent cytotoxicity). The significant improvement in cancer cell cytotoxicity that was observed when the Preparations were combined with Trastuzumab warrants immediate further investigation in breast cancer patients." Dr. Fritsche continued, "We look forward to the next step of initiating clinical trials of the Aion Mushroom Preparations with and without Herceptin (and other trastuzumab biosimilars) for the treatment of HER2+ breast cancer patients as well as the Aion Mushroom Preparations alone in ER+/PR+ breast cancer and triple-negative breast cancer patients."


"Each year more than 1.6 million new cases of breast cancer are diagnosed globally, making it the most common cancer among women, and more than 500,000 women will die of the disease," said Graham Simmonds, Executive Vice Chair and CEO of Aion Therapeutic. He added, "We are excited that these Aion Mushroom Preparations that have shown very encouraging initial test results will be developed to be transformative in how women are treated globally."


Isracann Biosciences Inc. (CSE: IPOT) (OTC: ISCNF) an Israel-based company focused on becoming a premier low cost, high quality cannabis producer/distributor announced that it has been granted a Foreign Owners Cannabis License by the Israeli Minister of Health. This important event paves the way to conclude a number of outstanding key partnership and regulatory considerations in preparation for commercial operations.


In a press release issued on March 24, 2020, Isracann announced its entry into a joint venture (JV) agreement as part of a phased partnership of two near-term farm operations located in Ein Hahoresh, Israel. The agreement included an equitable sharing arrangement of both operating costs and revenue through participatory agreements comprising construction services, growing services, land lease agreements, IMCA licenses, and a number of sub agreements establishing and defining the various rights of all parties. Today’s announcement represents the removal of regulatory ownership barriers in order to fully execute the terms of the JV plan.


The highly sought-after foreign owners license significantly legitimizes the Company’s presence in Israel. There are only a small number of foreign owned sector participants who have obtained similar licencing, and Isracann is now favourably positioned to leverage certain advantages. Ownership licensing allows for greater access to domestic partnerships, increased participation in state-sponsored initiatives, and enhances access to financing. It also simplifies the Company’s ability to undertake domestic acquisitions, including the conclusion of its planned purchase of a third-party participant in the JV which would result in Isracann increasing its ownership position to 50%.


In related news, the Company has concluded all requisite construction and infrastructural installations in preparation for the commencement of planting and subsequent production at its Hefer Valley-based Ein Hahoresh Farm. Largely due to COVID-19 related delays, Isracann has a final regulatory hurdle to conclude which appears to be moving closer to conclusion. Based on discussions with our regional consultants, we are waiting for an inspection by law enforcement officials and concurrent Ministry of Health approvals. It is our understanding that scheduling for the inspection is imminent. Upon receipt, Isracann will have full approval to begin planting.


Regarding the recently announced medical cannabis import partnership LOI, Isracann is working diligently with the Israeli partner to conclude the agreement for the importation of Canadian products on an expedited basis. Additionally, Isracann is finalizing an agreement with its Canadian partners to secure high-grade genetic material for introduction into its Israeli-based genomics program. While regional strains have certain inherently excellent traits, Isracann aims to broaden product diversity, and through expert agronomy to achieve a selection of world-class offerings.


Isracann CEO, Darryl Jones states, “We continue to push ahead on multiple fronts. From product importation to new genetics programs on the one hand, today we also celebrate our official approval as foreign owners in this exciting sector. Now we can truly dig in to finalize matters and accelerate our efforts to fully enter the commercial marketplace. We’ve been in communication with all the relevant parties and now with the licensing in-place, a number of initiatives will be triggered almost immediately and should result in an accelerated pace towards revenue generation. We have to admit that we always thought the pandemic would create a delay, and it could have been worse. In the meantime, we have by no means been standing still and have used the opportunity to invest in added value and develop our relations throughout the region. Once again we thank our Israeli team of consultants and stakeholders who have proven to be invaluable at representing our interests so effectively and who share our vision for success.”


Canopy Growth Corporation (TSX: WEED) (NASDAQ: CGC), a world-leading diversified cannabis, CBD and vaporization device company, today announced Southern Glazer's Wine & Spirits, the world's pre-eminent distributor of beverage alcohol, as the distribution partner for its U.S. portfolio of CBD-infused beverages. This partnership announcement follows the recent launch of Quatreau – Canopy's first line of CBD-infused beverages sold in the U.S market.


"Through this groundbreaking partnership, we will leverage Southern Glazer's established distribution network to bring our CBD beverage portfolio to retailers and consumers across the U.S. market," said Julious Grant, Chief Commercial Officer, Canopy Growth. "The leadership team at Southern Glazer's shares our values, priorities, and future-forward view of the category. Together, we are committed to creating an immediate strategic route to market for Canopy's premium CBD beverages."


Southern Glazer's will distribute Canopy Growth's CBD beverages, beginning with its CBD-infused sparkling water brand Quatreau™, across seven states, with additional states in the months to come. Southern Glazer's will be selling Quatreau™ through its existing commercial infrastructure, including its industry-leading Proof® e-commerce platform at Canopy Growth is one of the first U.S. CBD beverage producers to access the nationwide network of a large-scale alcohol distributor to reach consumers across the U.S. at mainstream retail stores. The agreement also showcases the benefits of the company's strategic relationship with Constellation Brands, the global beverage leader.


"This agreement reinforces our consumer-focused approach to identifying emerging growth areas where we can add value for our customers," said David Chaplin, Chief Growth Officer, Southern Glazer's Wine & Spirits. "There is strong consumer interest in the CBD-infused beverage category and our distribution network is uniquely positioned to deliver the most efficient and effective route-to-market for CBD suppliers and retail customers. We're proud to align with Canopy Growth, a company well-positioned to lead this product category with a portfolio of premium, highly desirable consumer brands."


"Innovation in the beverage industry like we are seeing from Canopy Growth brings new energy to the marketplace and increases the level of consumer interest in all our products," added John Wittig, Chief Commercial Officer, Southern Glazer's Wine & Spirits. "We are excited to be adding Quatreau as the first CBD-infused beverage in our portfolio."


Quatreau sparkling water contains 20 mg of premium, U.S. grown hemp-based CBD, in four refreshing flavors: Cucumber + Mint, Passion Fruit + Guava, Blueberry + Acai, and Ginger + Lime. With an MSRP of $3.99 per 12-ounce can, Quatreau is a functional zero-sugar drink that delivers a natural, low calorie beverage alternative. The stateside launch follows the successful 2020 rollout of Quatreau in Canada, where it is now the top-selling ready-to-drink CBD beverage.



Once again, today’s podcast is sponsored by Phyto Extractions Inc. (CSE:XTRX), an agricultural-scale cannabis extraction, distillation and product manufacturer located in Langley, BC at its co-located Health Canada Licensed Standard Processing (extraction, no cultivation), Sales (extracts, topicals, and edibles) through Adastra Labs Inc. and Analytical Testing Laboratory through Chemia Analytics Inc. Adastra Labs also has a pending Health Canada R&D license amendment.


Investor ideas reminds all listeners to read our disclaimers and disclosures on the website and that this podcast is not an endorsement to buy products or services or securities. Investors are reminded all investment involves risk and possible loss of investment.


Learn more about our cannabis podcasts at


 Investors can trade these stocks and other ideas on our site using our  list of top stock trading apps including Robinhood , Acorn, Stash  and others.

To hear more podcasts visit:

The podcasts are also available on iTunes ( Apple Podcasts) ,  Audible , Spotify, Tunein, Stitcher,, iHeartRadio ,  Google Play Music and most audio platforms available.


Potcasts is now a certified word mark Trademark on the blockchain through Cognate, Inc. CM Certification-Registration Number: 10468217708


About - News that Inspires Big Investing Ideas is a recognized news source publishing third party news, research and original financial content. Learn about investing in stocks and sector trends with our news alerts, articles, podcasts and videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech, water, renewable energy and more. Investor Idea’s original branded content includes the following podcasts and columns : Crypto Corner , Play by Play sports and stock news column, Investor Ideas Potcasts Cannabis News and Stocks on the Move podcast and column,  Cleantech and Climate Change , Exploring Mining  the AI Eye .

Disclaimer/Disclosure: is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers.  Contact management and IR of each company directly regarding specific questions. More disclaimer info: Learn more about publishing your news release and our other news services on the newswire and

Global investors must adhere to regulations of each country. Please read privacy policy:


Investor Ideas does not condone the use of cannabis except where permissible by law. Our site does not possess, distribute, or sell cannabis products.


Learn more about sponsoring this podcast or be a guest and our other branded content opportunities at


Follow us on Twitter

Follow us on Facebook

Follow us on YouTube

Download our Mobile App for iPhone and Android 

Join our Investor Club



800 665 0411



  Get more Cannabis Stock Investor Ideas – news, articles, podcasts and stock directory

No comments:

Post a Comment